The MRC does not normally allocate funding for specific disease areas and future research funding is dependent on the quality and strategic relevance of proposals submitted by the research community and is determined through peer review. Information on future funding that may be awarded for this area is not available. However, the MRC would welcome proposals which may support research leading to the development of genetic therapies to treat cancer in children. This may include fundamental research through to pre-clinical development, and early clinical testing of novel therapeutics, devices and diagnostics.
In 2010 the MRC's overall expenditure on cancer was £107.9 million(1). This includes a broad portfolio of site-specific and general underpinning cancer research some of which will be relevant to cancer in children. The MRC does not hold a breakdown of expenditure on research directly relating to research and development of genetic therapies to treat cancer in children. It would not be possible to undertake the necessary analysis in the time available.
(1) Source—National Cancer Research Institute CaRD